Concerned about your investment in Romark Global Pharma?
Are you concerned about your investment in Romark Global Pharma? If so, the securities attorneys at The White Law Group may be able to help you by filing a FINRA Dispute Resolution claim against the brokerage firm that sold you the investment.
Romark Global Pharma develops small molecules for treating infectious diseases and cancer as well as providing antiviral drugs.
The company, based in Tampa, Florida, filed a form D to raise capital from investors in 2017. The total offering amount sold was purportedly $13,835,000, according to the Reg D.
Filing a Complaint against your Brokerage Firm
The White Law Group is investigating the liability that FINRA registered brokerage firms may have for improperly recommending high-risk investments to investors.
The problem with pharma investments is that they typically involve a high degree of risk. Broker dealers are required to perform adequate due diligence on any investment they recommend and to ensure that all recommendations are suitable for the investor. Firms that fail to do so, may be held responsible for any losses in a FINRA arbitration claim.
If you have concerns regarding investment losses in Romark Global Pharma, please call the securities attorneys at The White Law Group for a free consultation at 888-637-5510.
The White Law Group, LLC is a national securities fraud, securities arbitration, investor protection, and securities regulation/compliance law firm with offices in Chicago, Illinois.
For more information on The White Law Group and its representation of investors in FINRA arbitration claims, visit https://www.whitesecuritieslaw.com.
Tags: Romark Global Pharma class action, Romark Global Pharma complaints, Romark Global Pharma investigation, Romark Global Pharma investment, Romark Global Pharma lawsuit, Romark Global Pharma news, Romark Global Pharma update Last modified: January 13, 2021